CAS: 941294-57-1; 5-Bromo-2-Iodo-4-Methylpyridine
该化合物是一种环状的异环有机化合物,其特点是有六人组成的芳香环,内含一个氮原子;该化合物有两种卤素替代成分:5点的溴原子和2点的碘原子,以及4点的环的甲基组;这些替代成分的存在影响其化学反应和物理特性,例如溶液和沸点.通常,这种化合物由于电内生具有中度到高度的再活性,可参与核分裂替代反应;此外,该甲基组可影响分子的心智特性和电子特性,并可能影响分子在各种化学反应中的行为. 5-Bromo-2-iodo-4-甲基丙烯可被用于有机合成,特别是用于发展药物或农业化学,因为其独特的结构特征可以进一步实现功能化.
- 英文名称5-Bromo-2-Iodo-4-Methylpyridine
- 中文名称5-溴-2-碘-4-甲基吡啶
- IUPAC名称5-bromo-2-iodo-4-methylpyridine
- 其它别名5-溴-2-碘-4-甲基砒啶; Pyridine,5-Bromo-2-Iodo-4-Methyl-
- CAS编号941294-57-1
- MFCD编号:MFCD09801049
- 分子式:C6H5BrIN分子量:297.92
- 产品CID: 1988104
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
1289018-37-6 376587-52-9 1008361-77-0物理性质
MSDS等安全信息
上下游产品
CAS号3430-26-0 2,5-二溴-4-甲基吡啶 | CAS号886364-94-9 5-溴-4-甲基吡啶-2-甲醛合成工艺路线路线简述
- 合成目标产物 5-Bromo-2-Iodo-4-Picoline 主要起始原料 2,5-Dibromo-4-Methylpyridine
- 3430-26-0 = 941294-57-1
反应条件:1.1 Reagents: Acetyl Chloride,Sodium Iodide Solvents: Acetonitrile; 0 °C -> 90 °C; 16 H,90 °C
标题:Preparation Of Arylamide Pyridine Oxides As Factor Xia Inhibitors For The Treatment And Prevention Of Thrombosis And Related Diseases
参考文献:United States]
3430-26-0 = 941294-57-1
反应条件:1.1 Reagents: Acetyl Chloride,Sodium Iodide Solvents: Acetonitrile; 3 H,Rt1.2 Reagents: Sodium Bicarbonate Solvents: Water; Neutralized,Rt
标题:Isoxazoline Derivatives As Insecticides And Their Preparation And Use
参考文献:World Intellectual Property Organization
📜2,5-二溴-4-甲基吡啶置于乙酰氯,Sodium Iodide,碳酸氢钠体系中,用 乙腈,水 作为反应溶剂,化学反应 3.0H,反应生成 5-溴-2-碘-4-甲基砒啶
参考文献:Insecticidal Compounds Based On Isoazoline Derivatives
标题:Insecticidal Compounds Based On Isoazoline Derivatives
摘要:本发明涉及式(I)的化合物:其中a1,A2,A3,A4,G1,L,Y1,Y2,Y3,Y4,R1,R2,R3和r4如权利要求1所定义;或其盐或n-氧化物.此外,本发明涉及制备式(I)化合物的中间体,包含它们的组合物以及使用它们来对抗和控制昆虫,螨虫,线虫和软体动物害虫的方法.
海关参考信息
- 2933310010-吡啶
2939800000-其他生物碱 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
